Fundraising Fox

Satsuma Pharmaceuticals

South San Francisco, US · Founded 2016 · Delaware corporation · 3 known investors

satsumarx.com ↗

Satsuma Pharmaceuticals is a pre-commercial biopharmaceutical company developing therapies for people living with migraine, including an FDA-approved treatment for acute migraine. Its products use a dry-powder inhalation delivery technology (the SMART platform) originally developed in Kagoshima, Japan.

BiotechMedical Devices

Founders & leadership

HL
Heath LukatchDirector
JK
John KollinsExecutive Officer, Director
MR
Michael RiebeDirector
RS
Rajeev ShahDirector
TI
Tadayoshi IwashimaExecutive Officer
TK
Thomas KingDirector
TB
Thomas B. KingPresident and Board Director
RJ
Rob JanoskyChief Commercial Officer
TO
Tom O'NeilChief Financial Officer
DP
David PrichardChief Operating Officer
KN
Koji NakajimaHead of Corporate Strategy

Investors · 3

OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
Vivo CapitalPalo Alto · $10M – $50M
Red Tree VenturereportedSan Diegovia Heath Lukatch · board

Reported raises · per SEC filings

Form D private placements
▶$12.1MraisedFeb 2018 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Heath LukatchDirector
  • John KollinsExecutive Officer, Director
  • Michael RiebeDirector
  • Rajeev ShahDirector
  • Tadayoshi IwashimaExecutive Officer
  • Thomas KingDirector
Offering amount
$12.3M
Amount sold
$12.1M
Minimum investment
$1
First sale
Dec 2016
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.